Vanda Pharmaceuticals Inc.’s compensation committee on Feb. 18, 2026 awarded 2025 annual cash bonuses to its named executive officers, including $834,326 to CEO and Chairman Mihael H. Polymeropoulos, $272,129 to CFO Kevin Moran, $272,129 to SVP Business Development Gunther Birznieks, $281,686 to CMO Joakim Wijkstrom, and $272,129 to General Counsel Timothy Williams. The committee also approved 2026 base salaries and target bonus levels, setting Polymeropoulos’s salary at $994,625 with an 80% target bonus, and salaries of $576,735–$596,990 with 45% target bonuses for the other executives. In addition, the committee granted RSUs and performance-based PSUs, including 525,000 RSUs and 175,000 target PSUs to Polymeropoulos and 125,000 RSUs plus 40,000 target PSUs to each of the other named executives, with PSUs tied to relative total shareholder return versus the Nasdaq Biotechnology Index over a three-year period ending Dec. 31, 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-009805), on February 19, 2026, and is solely responsible for the information contained therein.